Serial circulating tumor DNA (ctDNA) monitoring is emerging as a non-invasive strategy to
predict and monitor immune checkpoint blockade (ICB) therapeutic efficacy across cancer …

Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with
cancer. However, existing biomarkers do not reliably predict treatment response across …

The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced
cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n= 978) …

Purpose: Decisions to continue or suspend therapy with immune checkpoint inhibitors are
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …

Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint
inhibitors (ICIs) can produce remarkably durable responses, most patients develop early …

PURPOSE As immune checkpoint inhibitors (ICI) become increasingly used in frontline
settings, identifying early indicators of response is needed. Recent studies suggest a role for …

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics, triggering
studies to understand the molecular and cellular wiring of response and resistance. Our …

Background Despite treatment advancements with immunotherapy, our understanding of
response relies on tissue-based, static tumor features such as tumor mutation burden (TMB) …

Purpose: To explore relationships between biological gene expression signatures and
pembrolizumab response. Experimental Design: RNA-sequencing data on baseline tumor …

PURPOSE Immune checkpoint inhibitors (ICIs) are increasingly being used in non–small-
cell lung cancer (NSCLC), yet biomarkers predicting their benefit are lacking. We evaluated …